Navigation Links
Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial
Date:9/19/2011

ANN ARBOR, Mich., Sept. 19, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that the 150th patient has been enrolled in the randomized, double-blind, placebo-controlled, multi-center clinical trial of its Trimesta™ (oral estriol) drug candidate for relapsing-remitting multiple sclerosis (MS) in women, per the original protocol. The Company also announced that Rhonda Voskuhl, M.D., Director, University of California, Los Angeles (UCLA) Multiple Sclerosis Program, UCLA Department of Neurology, and lead Principal Investigator of this Phase II clinical trial, has funding available to continue enrollment at all 15 centers, therefore, increasing the power of the trial. It is anticipated that the remaining grant funding will allow for the enrollment of an additional 10-20 patients.

"We are excited to announce the enrollment of the 150th MS patient in this clinical trial, achieving our original targeted goal for enrollment. I am also very pleased that we have funds available to continue enrolling additional patients in this landmark MS trial," said Dr. Voskuhl. "Of the 400,000 people in the U.S. afflicted with MS, approximately 85% are initially diagnosed with relapsing-remitting MS, which is characterized by relapses, or attacks of declining neurologic function, followed by periods of remission. As we continue to dose and monitor each MS patient enrolled in the trial over a two year period, we would expect to demonstrate a statistically significant reduction in the rate of relapses in the patients treated with oral Trimesta."

"Completing enrollment in the Trimesta MS clinical trial as originally prescribed in the protocol is a significant milestone for Adeona and for MS patients, as it brings us one step closer to a potential treatment for women sufferin
'/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Adeona Appoints George A. Eby to Scientific Advisory Board
2. Adeona Reports Second Quarter 2011 Financial Results
3. Adeona to Host Second Quarter 2011 Investor Conference Call
4. Adeona Executes Agreement to Initiate Phase IIb Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrigs Disease (ALS)
5. Adeona Reports 1st Quarter 2011 Financial Results
6. Adeona to Host First Quarter 2011 Investor Conference Call
7. Adeona Executes Manufacturing and Supply Agreement with TG United for reaZin™
8. Adeonas Clinical Study of reaZin™ Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper
9. Adeona to Host Conference Call
10. Adeona to Raise $3.5 Million in Registered Direct Offering
11. Adeona Reports 2010 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... Mass. , July 6, 2015 Hologic, ... Company plans to release its financial results for the ... 2015, after the market closes.  In conjunction with the ... at 4:30 p.m. Eastern Time. Interested participants ... the United States ) or 719-325-4804 ...
(Date:7/6/2015)... 2015 E-QURE Corp (OTCQB: EQUR), today announced that ... VirtualInvestorConferences.com on July 9, 2015. DATE: Thursday, July ... This will be a live, interactive ... company questions in real-time - both in the presentation ... If attendees are not able to join the event ...
(Date:7/6/2015)... FARMINGTON, Conn. , July 6, ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... Series E warrants to purchase 21,917,808 shares of ... purchase 2,191,781 shares of its common stock.  Certain ...
Breaking Medicine Technology:Hologic to Announce Financial Results for the Third Quarter of Fiscal 2015 on Wednesday, July 29, 2015 2E-QURE Corp to Webcast, Live, at VirtualInvestorConferences.com July 9 2Palatin Technologies Completes $30 Million Financing 2Palatin Technologies Completes $30 Million Financing 3Palatin Technologies Completes $30 Million Financing 4Palatin Technologies Completes $30 Million Financing 5
... 7 NeuroVasx, Inc. announced,today the completion of a private ... of Minneapolis, MN and the Stephens Group of Little,Rock, AR. ... also announced completion of long term follow up on 20,patients ... which was completed in May. The company intends to announce ...
... Genomic Health,Inc. (Nasdaq: GHDX ) today announced ... DX(R) breast cancer test are scheduled to be ... Symposium, taking place,December 13-16, 2007. Oncotype DX is ... the likelihood of recurrence and the likelihood,of chemotherapy ...
Cached Medicine Technology:Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium 2Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium 3
(Date:7/6/2015)... London, UK (PRWEB) , ... July 06, 2015 , ... ... 5.58 billion in 2014. It is expected to grow at a CAGR of over ... by 2021. , The growth is likely to be mainly spurred by an anticipated ...
(Date:7/6/2015)... ... July 06, 2015 , ... Cancer ... cancer patients, caregivers and medical professionals to chat with the CHN patient services ... , “Receiving a cancer diagnosis is often the most traumatic experience of a ...
(Date:7/6/2015)... ... , ... In a split second, breaking a bone can cause loss of ... fracture through the bone health screenings conducted by American Bone Health trained Peer Educators ... residents need this information to remain independent and strong for many more years,” according ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... Randstad Technologies selected Aspect Software Unified IP contact center solution hosted by Promero. ... Aspect Unified IP as its future call center platform. , Promero will ...
(Date:7/5/2015)... Minneapolis, MN (PRWEB) , ... July 06, 2015 ... ... in the ancillary benefits market, is excited to announce the next generation of ... Plus and Advantage plans to now include two network options—Maximum Allowable Charge (MAC) ...
Breaking Medicine News(10 mins):Health News:APAC Rheumatoid Arthritis Therapeutics Market to Reach Value of USD 6.9 Billion by 2021, Says GBI Research in Its New Report Now Available at MarketPublishers.com 2Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2Health News:National Bone Health Screening and Awareness Day 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 3Health News:Security Life Insurance Company of America Launches the Next Generation of PrimeStar Individual Dental Insurance Plans 2
... Reporter , MONDAY, Feb. 28 (HealthDay News) -- The battle of ... players in the fight to reduce waistlines, two new studies report. ... told by their doctors that they are overweight or obese, they ... likely to want to lose weight and to try to lose ...
... State University School of Medicine physician-researcher has developed a ... The treatment is based on a naturally occurring human ... cells into killing themselves. The unique concept, patented ... cells that are resistant to routine treatments such as ...
... Feb. 28, 2011 Los Angeles Biomedical Research ... Inc., a Japanese biotechnology firm, have entered into a ... in regenerative medicine, "Cell Sheet Engineering," LA BioMed President ... "LA BioMed is working to accelerate the pace of ...
... , A new University of Colorado Boulder study indicates ... in helping to treat people with mild traumatic brain ... U.S. war veterans returning home. The study involved ... are used to stimulate particular points on a person,s ...
... (BUSM) have found that patients with node negative T3 ... surgery had more than three times the survival rate ... appear on-line in the Journal of Thoracic and ... total of 110 patients who underwent surgical resection for ...
... brain imaging study at the U.S. Department of Energy,s (DOE) ... subjects and those who compulsively overeat, or binge: In binge ... smell of favorite foods triggers a spike in dopamine - ... - published online on February 24, 2011, in the journal ...
Cached Medicine News:Health News:Doctors Can Influence Patients to Lose Weight: Studies 2Health News:Doctors Can Influence Patients to Lose Weight: Studies 3Health News:WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves 2Health News:WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves 3Health News:WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves 4Health News:LA BioMed and CellSeed to launch joint research project on regenerative medicine technology 2Health News:U. of Colorado study shows acupressure effective in helping to treat traumatic brain injury 2Health News:U. of Colorado study shows acupressure effective in helping to treat traumatic brain injury 3Health News:U. of Colorado study shows acupressure effective in helping to treat traumatic brain injury 4Health News:Binge eaters' dopamine levels spike at sight, smell of food 2Health News:Binge eaters' dopamine levels spike at sight, smell of food 3
... The Acuity LT Central Monitoring Station ... self-contained and ready to go right out ... patient surveillance in specific care areas rather ... the ICU. As patient-to-caregiver ratios continue to ...
... The reliable and easy-to-use 3800 and ... advancedfeaturing TruTrak+ technology, the proprietary clinical ... products offer you improved performance:, ... are submitted to rigorous environmental/ mechanical ...
... for Clinical Professionals and Researchers., ,S/5 Collect ... and efficient way to collect data from Datex-Ohmeda ... days at selectable time intervals. With S/5 Collect ... the monitor via an interface cable or connect ...
... information. , ,S/5 Clinical Communications is ... that help you and your care team ... will have access to essential patient information ... your care team and specialists, independent of ...
Medicine Products: